Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial
This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n=109) or placebo (n=110). No patients received statins prior to...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Evidence-Based Complementary and Alternative Medicine |
Online Access: | http://dx.doi.org/10.1155/2016/7960503 |
id |
doaj-8fab3f5513bf4b04982a39a96d4491d3 |
---|---|
record_format |
Article |
spelling |
doaj-8fab3f5513bf4b04982a39a96d4491d32020-11-24T21:04:42ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882016-01-01201610.1155/2016/79605037960503Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized TrialLei Wang0Xujie Zhao1Shuai Mao2Shaonan Liu3Xinfeng Guo4Liheng Guo5Tinghai Du6Haiyu Yang7Fuhai Zhao8Keng Wu9Hongliang Cong10Yang Wu11Phillip C. Yang12Keji Chen13Minzhou Zhang14Department of Critical Care Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, ChinaDepartment of Critical Care Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, ChinaDepartment of Critical Care Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, ChinaChina-Australia International Research Centre for Chinese Medicine (CAIRC-CM), Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou 510120, ChinaChina-Australia International Research Centre for Chinese Medicine (CAIRC-CM), Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou 510120, ChinaDepartment of Critical Care Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, ChinaDepartment of Cardiovascular Medicine, First Affiliated Hospital of Henan College of TCM, Zhengzhou 450004, ChinaDepartment of Cardiovascular Medicine, Wuyi Hospital of TCM of Jiangmen City, Jiangmen 529000, ChinaDepartment of Cardiology, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100091, ChinaDepartment of Cardiology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524023, ChinaDepartment of Cardiology, Tianjin Chest Hospital, Tianjin 300051, ChinaDepartment of Cardiovascular Medicine, Oriental Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100078, ChinaDepartment of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADepartment of Cardiology, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100091, ChinaDepartment of Critical Care Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, ChinaThis study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n=109) or placebo (n=110). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p=0.04) and 24 h (23.9% versus 38.2%, p=0.02) after PCI. The 30-day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p=0.06). The incidence of MACE at 90-day follow-up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p=0.03). The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p=0.04). These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI.http://dx.doi.org/10.1155/2016/7960503 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lei Wang Xujie Zhao Shuai Mao Shaonan Liu Xinfeng Guo Liheng Guo Tinghai Du Haiyu Yang Fuhai Zhao Keng Wu Hongliang Cong Yang Wu Phillip C. Yang Keji Chen Minzhou Zhang |
spellingShingle |
Lei Wang Xujie Zhao Shuai Mao Shaonan Liu Xinfeng Guo Liheng Guo Tinghai Du Haiyu Yang Fuhai Zhao Keng Wu Hongliang Cong Yang Wu Phillip C. Yang Keji Chen Minzhou Zhang Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial Evidence-Based Complementary and Alternative Medicine |
author_facet |
Lei Wang Xujie Zhao Shuai Mao Shaonan Liu Xinfeng Guo Liheng Guo Tinghai Du Haiyu Yang Fuhai Zhao Keng Wu Hongliang Cong Yang Wu Phillip C. Yang Keji Chen Minzhou Zhang |
author_sort |
Lei Wang |
title |
Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial |
title_short |
Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial |
title_full |
Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial |
title_fullStr |
Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial |
title_full_unstemmed |
Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial |
title_sort |
efficacy of danlou tablet in patients with non-st elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from a multicentre, placebo-controlled, randomized trial |
publisher |
Hindawi Limited |
series |
Evidence-Based Complementary and Alternative Medicine |
issn |
1741-427X 1741-4288 |
publishDate |
2016-01-01 |
description |
This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n=109) or placebo (n=110). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p=0.04) and 24 h (23.9% versus 38.2%, p=0.02) after PCI. The 30-day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p=0.06). The incidence of MACE at 90-day follow-up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p=0.03). The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p=0.04). These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI. |
url |
http://dx.doi.org/10.1155/2016/7960503 |
work_keys_str_mv |
AT leiwang efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT xujiezhao efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT shuaimao efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT shaonanliu efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT xinfengguo efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT lihengguo efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT tinghaidu efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT haiyuyang efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT fuhaizhao efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT kengwu efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT hongliangcong efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT yangwu efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT phillipcyang efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT kejichen efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial AT minzhouzhang efficacyofdanloutabletinpatientswithnonstelevationacutecoronarysyndromeundergoingpercutaneouscoronaryinterventionresultsfromamulticentreplacebocontrolledrandomizedtrial |
_version_ |
1716770160898998272 |